Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study.

Autor: Bao H; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China.; Department of Oncology, Chongqing University Three Gorges Hospital/Chongqing Three Gorges Central Hospital, Chongqing, 404100, China., Ma LZ; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China., Zhao C; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China., Yu M; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China., Zhang B; Department of Oncology, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China., Zhang J; Department of Otorhinolaryngology, Zhujiang Hospital, Southern Medical University, 253 Gongye Road, Guangzhou, 510282, Guangdong, China., Peng G; Department of General Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Lin X; Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China., Fang Y; Department of Emergency, Chongqing Banan District People's Hospital, Chongqing, 401320, China., Bao H; Department of Oncology, Chongqing University Three Gorges Hospital/Chongqing Three Gorges Central Hospital, Chongqing, 404100, China., Ma S; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China. mashudong@aliyun.com.
Jazyk: angličtina
Zdroj: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Mar; Vol. 149 (3), pp. 1185-1193. Date of Electronic Publication: 2022 Apr 04.
DOI: 10.1007/s00432-022-03935-0
Abstrakt: Purpose: Primary pulmonary lympho-epithelioma-like carcinoma (PPLELC) is a rare subtype of primary non-small cell lung cancer (NSCLC). Currently, there is still lack of research data on anti-angiogenic therapy of advanced PPLELC. The purpose of this study was to investigate the efficacy and safety of anti-angiogenic therapy combined with chemotherapy compared with traditional chemotherapy for these patients.
Methods: Advanced PPLELC patients admitted to six grade A hospitals from January 2013 to January 2021 were selected. The patients received anti-angiogenic therapy combined with chemotherapy (AT group) or chemotherapy (CT group) alone.
Results: A total of 65 patients were included in this study, including 31 patients in the AT group treated with anti-angiogenic therapy combined with chemotherapy and 34 patients in the CT group treated with chemotherapy alone. As of October 1, 2021, the median progression-free survival (PFS) in the AT group was 11.2 months [95% confidence interval (CI), 5.9-16.5]. The median PFS in the CT group was 7.0 months [95%CI, 5.1-8.9] [Hazard Ratio (HR), 0.49; 95%CI, 0.29-0.83; P = 0.008]. The 1-year PFS rates were 41.9% and 17.6%, respectively. The overall response rates (ORR) of two groups were 45.2% (95% CI, 0.27-0.64), 38.2% (95% CI, 0.21-0.56), (P = 0.571). The disease control rates (DCR) of two groups were 93.5% (95% CI, 0.84-1.03), 88.2% (95% CI, 0.77-1.00), (P = 0.756).
Conclusion: Among patients with advanced PPLELC, the PFS of patients with anti-angiogenic therapy combined with chemotherapy is better than that of patients with chemotherapy alone. Anti-angiogenic therapy combined with chemotherapy is an optional treatment scheme.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: